Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial

DSpace Repository

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial

Author: Motzer, Robert J.; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T.; Shah, Amishi Y.; Suarez, Cristina; Hamzaj, Alketa; Porta, Camillo; Hocking, Christopher M.; Kessler, Elizabeth R.; Gurney, Howard; Tomita, Yoshihiko; Bedke, Jens; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Apolo, Andrea B.; Choueiri, Toni K.
Tübinger Autor(en):
Bedke, Jens
Published in: Lancet Oncology (2022), Bd. 23, H. 7, S. 888-898
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(22)00290-X
ISSN: 1470-2045
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)